Ettore Mearini

TL;DR: In SCI patients with refractory NDO who do not want or are unfit for invasive reconstructive surgery, BoNTA intravesical treatment represents a valid alternative to control DO and urinary incontinence and to preserve upper urinary tract function over a long-term follow-up.

TL;DR: Intravesically injected botulinum toxin A is effective for short-term management of refractory painful bladder syndrome, but the beneficial effects decreased progressively within a few months after treatment.

TL;DR: The new beneficial effect that is reported in a small study sample encourages larger trials to confirm botulinum toxin type A injection into the detrusor muscle as an effective and safe treatment for refractory overactive bladder symptoms and detrusors overactivity related to Parkinson's disease and multiple system atrophy.

TL;DR: Following RRP detrusor hypocontractility, decreased bladder compliance, and ISD represent de novo dysfunction probably due to bladder denervation during surgery, and become established conditions over time in about 30% of patients.

TL;DR: A case‐control study is undertaken in order to elucidate the association between polymorphisms in some metabolizing genes with the risk of prostate cancer (PCa).